Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12445760 | 0.85 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL12445755 | 0.79 | CYP1A2 (0.39) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL12445752 | 0.76 | CSNK2A2 (0.38) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL15948192 | 0.69 | AKR1B1 (0.42) | CYP1A2HSD17B10 | |
| SCHEMBL12445751 | 0.68 | CYP1A2 (0.37) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL11268242 | 0.68 | CYP1A2 (0.37) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL503968 | 0.66 | AKR1B1 (0.41) | CYP1A2HSD17B10 | |
| SCHEMBL12445754 | 0.66 | GABRA5 (0.40) | CYP1A2GABRA5GABRB2HSD17B10 | |
| SCHEMBL12445758 | 0.65 | CSNK2A2 (0.43) | CYP1A2HSD17B10 | |
| SCHEMBL15948146 | 0.65 | AKR1B1 (0.39) | CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531498-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-9181238-B2 | N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG | 2013-06-06 | — | — | US | disclosed |
| WO-2011097526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143899-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | RAF1, BRAF, ARAF | CYP1A2 3240/4885GABRA5 3793/4885GABRB2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.